Profile Details

Create Project

★★★★★

☆☆☆☆☆

USD 150 /hr

★★★★★

☆☆☆☆☆

Hire Dr. Anthony O.

United Kingdom

USD 150 /hr

Freelance Expert in Therapeutic Antibody Discovery and Development. Strategy and Leadership in Start-up and CROs.

Profile Summary

20 years+ experience in leadership roles in antibody discovery and development. Generating fit-for-purpose platforms, managing CROs, Discovery Strategy, Sales and Market positioning.

Subject Matter Expertise

• ☆ Biochemistry
• ☆ Molecular Biology
• ☆ Monoclonal Antibody Production
• ☆ Biotechnology & Bioengineering
• ☆ Biological Systems Engineering
• ☆ Biological Engineering
• ☆ Biomarker Discovery
• ☆ Synthetic Biology
• ☆ Biosensors
• ☆ Biomolecular Engineering
• ☆ Antibody Engineering
• ☆ Drug Discovery
• ☆ Drug Target Identification
• ☆ Hit-to-Lead & Lead Optimization
• ☆ Drug Design
• ☆ Drug Development
• ☆ Biologic & Biosimilar Development
• ☆ Bioanalytical Testing
• ☆ Preclinical ADME/PK/PD
• ☆ Preclinical Research
• ☆ In vitro Preclinical Toxciology
• ☆ In vivo Preclinical Toxicology
• ☆ Immunotherapy
• ☆ Pharmaceutical Technology

Services

• Writing
• Research
• Consulting
• Product Development

Writing Technical Writing

Research Market Research, Feasibility Study, Technology Scouting, Fact Checking, Gray Literature Search, Scientific and Technical Research, Systematic Literature Review

Consulting Business Strategy Consulting, Scientific and Technical Consulting

Product Development Product Evaluation, Material Sourcing, Concept Development

Work Experience

Fractional CEO/CSO

Finn Therapeutics Ltd.

September 2023 - Present

Head of Discovery and Scientific Affairs

Fusion Antibodies plc.

March 2016 - Present

Education

PhD

Queens University Belfast

September 2009 - June 2013

Certifications

• Certification details not provided.

Publications

JOURNAL ARTICLE

Targeting Adrenomedullin in Oncology: A Feasible Strategy With Potential as Much More Than an Alternative Anti-Angiogenic Therapy @ARTICLE{10.3389/fonc.2020.589218, AUTHOR= {Vázquez, Ramiro and Riveiro, Maria E. and Berenguer-Daizé, Caroline and O’Kane, Anthony and Gormley, Julie and Touzelet, Olivier and Rezai, Keyvan and Bekradda, Mohamed and Ouafik, L’Houcine}, TITLE= {Targeting Adrenomedullin in Oncology: A Feasible Strategy With Potential as Much More Than an Alternative Anti-Angiogenic Therapy}, JOURNAL= {Frontiers in Oncology}, VOLUME= {10}, PAGES= {2678}, YEAR= {2021}, URL= {https://www.frontiersin.org/article/10.3389/fonc.2020.589218}, DOI= {10.3389/fonc.2020.589218}, ISSN= {2234-943X}, ABSTRACT= {The development, maintenance and metastasis of solid tumors are highly dependent on the formation of blood and lymphatic vessels from pre-existing ones through a series of processes that are respectively known as angiogenesis and lymphangiogenesis. Both are mediated by specific growth-stimulating molecules, such as the vascular endothelial growth factor (VEGF) and adrenomedullin (AM), secreted by diverse cell types which involve not only the cancerogenic ones, but also those constituting the tumor stroma (i.e., macrophages, pericytes, fibroblasts, and endothelial cells). In this sense, anti-angiogenic therapy represents a clinically-validated strategy in oncology. Current therapeutic approaches are mainly based on VEGF-targeting agents, which, unfortunately, are usually limited by toxicity and/or tumor-acquired resistance. AM is a ubiquitous peptide hormone mainly secreted in the endothelium with an important involvement in blood vessel development and cardiovascular homeostasis. In this review, we will introduce the state-of-the-art in terms of AM physiology, while putting a special focus on its pro-tumorigenic role, and discuss its potential as a therapeutic target in oncology. A large amount of research has evidenced AM overexpression in a vast majority of solid tumors and a correlation between AM levels and disease stage, progression and/or vascular density has been observed. The analysis presented here indicates that the involvement of AM in the pathogenesis of cancer arises from: 1) direct promotion of cell proliferation and survival; 2) increased vascularization and the subsequent supply of nutrients and oxygen to the tumor; 3) and/or alteration of the cell phenotype into a more aggressive one. Furthermore, we have performed a deep scrutiny of the pathophysiological prominence of each of the AM receptors (AM₁ and AM₂) in different cancers, highlighting their differential locations and functions, as well as regulatory mechanisms. From the therapeutic point of view, we summarize here an exhaustive series of preclinical studies showing a reduction of tumor angiogenesis, metastasis and growth following treatment with AM-neutralizing antibodies, AM receptor antagonists, or AM receptor interference. Anti-AM therapy is a promising strategy to be explored in oncology, not only as an anti-angiogenic alternative in the context of acquired resistance to VEGF treatment, but also as a potential anti-metastatic approach.}} . Frontiers in Oncology.

Greenfield RS, Herd TM, Date K, Cooper P, O'Kane A, Gardiner E, Maraveyas A(2018). Signal Transduction Peptide of Tissue Factor Phosphorylated at Ser258 and the Unphosphorylated STP in Urine Are Potential Biomarkers for Bladder Cancer . Clinical genitourinary cancer.

O'Kane AA, Elliott CT, Mooney MH(2014). Complex interactions between dioxin-like and non-dioxin-like compounds for in vitro cellular responses: implications for the identification of dioxin exposure biomarkers . Chemical research in toxicology.

O'Kane AA, Chevallier OP, Graham SF, Elliott CT, Mooney MH(2013). Metabolomic profiling of in vivo plasma responses to dioxin-associated dietary contaminant exposure in rats: implications for identification of sources of animal and human exposure . Environmental science & technology.

Yakkundi A, McCallum L, O'Kane A, Dyer H, Worthington J, McKeen HD, McClements L, Elliott C, McCarthy HO, Hirst DG, et al.(2013). The anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway . PloS one.

Vyas P, O'Kane AA, Dowell D(2012). Determination of vitamin B12 in infant formula and adult nutritionals by surface plasmon resonance: First Action 2011.16 (test kit method) . Journal of AOAC International.

Vyas P, O'Kane AA(2011). Determination of vitamin B12 in fortified bovine milk-based infant formula powder, fortified soya-based infant formula powder, vitamin premix, and dietary supplements by surface plasmon resonance: collaborative study . Journal of AOAC International.

Haughey SA, O'Kane AA, Baxter GA, Kalman A, Trisconi MJ, Indyk HE, Watene GA(2005). Determination of pantothenic acid in foods by optical biosensor immunoassay . Journal of AOAC International.